Jean-Paul DUTERTRE

Jean-Paul DUTERTRE has a strong background in pharmacovigilance and regulatory affairs. Jean-Paul is currently serving as the Head of Pharmacovigilance at Inventiva Pharma, a position they have held since February 2021. Prior to this, they worked at LFB as the Head of Global Safety Group and EEA-QPPV from September 2019 to February 2021. Jean-Paul also served as the EEA-QPPV at TESARO, Inc. from March 2019 to August 2019.

Jean-Paul's experience includes roles at SERB, where they worked as the Director of Medical Affairs and EEA-QPPV from an unspecified date in 2017 to February 2019, and as the EEA-QPPV from April 2012 to an unspecified date in 2017. Jean-Paul also served as the Vice-President of Safety and Pharmacovigilance at Leem from May 2014 to February 2019.

Prior to these positions, Jean-Paul worked at AB SCIENCE as the Associate Director of Pharmacovigilance and Regulatory Affairs from December 2011 to March 2012. Jean-Paul also held the EEA-QPPV position at Orphan Europe from May 2005 to an unspecified date in 2011, and at besins healthcare as the Director of Corporate Pharmacovigilance (EEA-QPPV) from an unspecified date in 2002 to 2005.

Jean-Paul began their career in pharmacovigilance at Eli Lilly and Company, where they worked as a Drug Safety Physician from an unspecified date in 2001 to 2002. Jean-Paul also worked at SmithKline Beecham (then GSK) as a Drug Safety Physician from an unspecified date in 1995 to 2001.

Jean-Paul DUTERTRE has attended the Faculté de Médecine Paris XI and Paris-Sud University (Paris XI) at some point, but the specific years, degrees, and fields of study are unknown.